Skip to main content
Mazen Noureddin, MD, Gastroenterology, Houston, TX

Mazen Noureddin MD MHSc

Hepatology & Liver Transplantation


Transplant Hepatologist, Houston Methodist Hospital, Director Houston Research Institute

Join to View Full Profile
  • 1155 Dairy Ashford RoadSte 200Houston, TX 77079

  • Phone+1 281-809-3234

  • Fax+1 281-809-3287

Dr. Noureddin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Duke School of Medicine
    Duke School of MedicineMHSc, Master's Health Sciences in Clinical Research, 2009 - 2018
  • University of California (San Diego) Medical Center
    University of California (San Diego) Medical CenterFellowship, Gastroenterology, 2011 - 2013
  • Clinical Center at the National Institutes of Health
    Clinical Center at the National Institutes of HealthFellowship, Transplant Hepatology, 2009 - 2011
  • University of Southern California/Los Angeles General Medical Center (USC/LA General)
    University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2005 - 2008
  • University of Aleppo Faculty of Medicine
    University of Aleppo Faculty of MedicineClass of 2002

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2022 - 2027
  • CA State Medical License
    CA State Medical License 2007 - 2025
  • VA State Medical License
    VA State Medical License 2008 - 2012
  • Gastroenterology
    American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

  • Top Doctors Pasadena Magazine 2014-2018
  • Visionary in Health Care American Liver Foundation, 2016

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.  
    Noureddin M1,2, Vipani A3, Bresee C4, Todo T5, Kim IK5, Alkhouri N6, Setiawan VW7, Tran T8,3, Ayoub WS8,3, Lu SC8,3, Klein AS5, Sundaram V8,3, Nissen NN5., American Journal of Gastrenterology, 6/8/2018
  • NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications for Liver Transplant and Ethnic and Gender Variances  
    Tsuyoshi Todo, Walid S Ayoub, Naim Alkhouri, Nicholas N Nissen, Vinay Sundaram, Shelly C Lu, Mazen Noureddin, Aarshi Vipani, Tram Tran, Andrew S Klein, Nature

Press Mentions

  • Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
    Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASHJune 26th, 2025
  • Rivus Pharmaceuticals Announces Positive Topline Results from Phase 2 M-ACCEL Trial of HU6 Showing Significant Reductions in Liver Fat in Patients with MASH
    Rivus Pharmaceuticals Announces Positive Topline Results from Phase 2 M-ACCEL Trial of HU6 Showing Significant Reductions in Liver Fat in Patients with MASHJune 24th, 2025
  • D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic Health
    D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic HealthJune 16th, 2025
  • Join now to see all

Other Languages

  • Arabic, Farsi, Spanish

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: